- Other backers included Portal Innovations, Alexandria Venture Investments and Linden Lake Labs
- The seed capital will fund the development of the company’s lead program that treats solid tumors and accelerate the expansion of its pipeline of programs
- As part of this financing, both William McKeon, president and CEO of the Texas Medical Center and Dr. Damir Illich, manager, life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors
CrossBridge Bio, a biotechnology company, has raised $10 million in seed financing.
TMC Venture Fund and CE-Ventures, the corporate venture capital platform of Crescent Enterprises led the round. Other backers included Portal Innovations, Alexandria Venture Investments and Linden Lake Labs.
The seed capital will fund the development of the company’s lead program that treats solid tumors and accelerate the expansion of its pipeline of programs.
“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” said Dr. Michael Torres, CEO of CrossBridge Bio in a statement. “Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments.”
As part of this financing, both William McKeon, president and CEO of the Texas Medical Center and Dr. Damir Illich, manager, life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.
Headquartered in Houston, CrossBridge Bio was founded in 2023.
- Other backers included Portal Innovations, Alexandria Venture Investments and Linden Lake Labs
- The seed capital will fund the development of the company’s lead program that treats solid tumors and accelerate the expansion of its pipeline of programs
- As part of this financing, both William McKeon, president and CEO of the Texas Medical Center and Dr. Damir Illich, manager, life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors
CrossBridge Bio, a biotechnology company, has raised $10 million in seed financing.
TMC Venture Fund and CE-Ventures, the corporate venture capital platform of Crescent Enterprises led the round. Other backers included Portal Innovations, Alexandria Venture Investments and Linden Lake Labs.
The seed capital will fund the development of the company’s lead program that treats solid tumors and accelerate the expansion of its pipeline of programs.
“We are thrilled to have the support of such experienced investors who share our vision of bringing transformative cancer therapies to patients in need,” said Dr. Michael Torres, CEO of CrossBridge Bio in a statement. “Our dual-payload ADC technology is designed to deliver synergistic therapeutic effects using highly stable linkers that ensure payload release only within the targeted cancer cells, thereby maximizing their therapeutic effectiveness while minimizing the liabilities associated with uptake in unintended tissues, as seen with many of today’s cancer treatments.”
As part of this financing, both William McKeon, president and CEO of the Texas Medical Center and Dr. Damir Illich, manager, life sciences of CE-Ventures, will join CrossBridge Bio’s board of directors.
Headquartered in Houston, CrossBridge Bio was founded in 2023.
